In conclusion, our present study demonstrates that prolonged exposure to a clinically relevant low‐dose of the DNA methyltransferase inhibitor decitabine significantly, but mildly delays leukemia progression in MLL‐rearranged ALL xenograft mouse models. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.